37937-62-5

Basic information

• Product Name: 5-Phenyl-1,2,4-oxadiazole-3-carboxylic acid
• Synonyms: 5-Phenyl-1,2,4-oxadiazole-3-carboxylic acid
• CAS NO: 37937-62-5
• Molecular Formula: C₉H₆N₂O₃
• Molecular Weight: 190.15554
• Mol File: 37937-62-5.mol
• Article Data: 4

Chemical Properties

• Melting Point: 119-120 °C
• Boiling Point: 400.4±28.0 °C(Predicted)
• Appearance: /
• Density: 1.393±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 2.77±0.10(Predicted)
• CAS DataBase Reference: 5-Phenyl-1,2,4-oxadiazole-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Phenyl-1,2,4-oxadiazole-3-carboxylic acid(37937-62-5)
• EPA Substance Registry System: 5-Phenyl-1,2,4-oxadiazole-3-carboxylic acid(37937-62-5)

Safety Data

• Hazardous Substances Data: 37937-62-5(Hazardous Substances Data)

Usage

General Description

5-Phenyl-1,2,4-oxadiazole-3-carboxylic acid is a chemical compound that belongs to the oxadiazole family. It is a heterocyclic compound containing a five-membered ring with oxygen and nitrogen atoms. 5-Phenyl-1,2,4-oxadiazole-3-carboxylic acid has a phenyl group attached to the oxadiazole ring, and a carboxylic acid functional group at the 3-position. It is a versatile molecule and has potential applications in medicinal chemistry, pharmaceuticals, and materials science. It has been studied for its anti-inflammatory, antimicrobial, and anticancer properties, and its unique structure makes it an interesting target for drug design and development.

Upstream product

• 10425-39-5 (4-amino-1,2,5-oxadiazol-3-yl)(phenyl)methanone 
• 37384-62-6 ethyl 5-phenyl-1,2,4-oxadiazole-3-carboxylate 
• 98-88-4 benzoyl chloride 
• 56952-04-6 methyl 2-N-benzoylamino-3-N,N-dimethylamino-2-propenoate 
• 37384-61-5 5-phenyl-1,2,4-oxadiazol-3-ylcarboxylic acid methyl ester 
• 1081533-58-5 C₁₁H₁₂N₂O₄ 
• 65-85-0 benzoic acid 

Downstream Products

• 34955-74-3 5-phenyl-1,2,4-oxadiazole-3-carboxamide 
• 7747-00-4 (5-phenyl-[1,2,4]oxadiazol-3-yl)-urea 
• 7746-97-6 5-phenyl-[1,2,4]oxadiazole-3-carbonyl azide 
• 92649-96-2 5-phenyl-[1,2,4]oxadiazole-3-carboxylic acid 2-diethylamino-ethyl ester 
• 97074-85-6 1-(2-dimethylamino-ethyl)-3-(5-phenyl-[1,2,4]oxadiazol-3-yl)-urea 
• 92697-71-7 1-(2-diethylamino-ethyl)-3-(5-phenyl-[1,2,4]oxadiazol-3-yl)-urea 
• 1552272-77-1 (3S,6S)-3,6-diisobutyl-4-(5-phenyl-1,2,4-oxadiazole-3-carbonyl)piperazin-2-one 
• 1613021-97-8 (S)-5-phenyl-N-(1-(pyrrolo[1,2-a]pyrazin-1-yl)pyrrolidin-3-yl)-1,2,4-oxadiazole-3-carboxamide 
• 1613021-95-6 (S)-N-(1-(imidazo[1,2-a]pyrazin-8-yl)pyrrolidin-3-yl)-5-phenyl-1,2,4-oxadiazole-3-carboxamide 

Relevant articles and documents

Discovery of Novel Aryl Carboxamide Derivatives as Hypoxia-Inducible Factor 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis

In order to discover novel hypoxia-inducible factor 1 (HIF-1) inhibitors for the cancer metastasis treatment, 68 new aryl carboxamide compounds were synthesized and evaluated for their inhibitory effect by dual luciferase-reporter assay. Based on five rounds of investigation on structure-activity relationships step by step, compound 30m was discovered as the most active inhibitor (IC50 = 0.32 μM) with no obvious cytotoxicity (CC50 > 50 μM). It effectively attenuated hypoxia-induced HIF-1α protein accumulation and reduced transcription of vascular epidermal growth factor in a dose-dependent manner, which was further demonstrated by its inhibitory potency on capillary-like tube formation, angiogenesis of zebrafish as well as cellular migration and invasion. Importantly, compound 30m exhibited antimetastatic potency in breast cancer lung metastasis in the mice model, indicating its promising therapeutic potential for prevention and treatment of tumor metastasis. These results definitely merit attention for further rational design of more efficient HIF-1 inhibitors in the future.

CXCR7 ANTAGONISTS

Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.